Bright Peak Therapeutics raised $90 million in a Series C financing round led by Johnson & Johnson Innovation. Proceeds from the Series C financing will be used to advance BPT567 into a Phase 1/2a clinical trial and accelerate a pipeline of next-generation immunotherapies. The Phase 1/2a study in solid tumors is expected to begin in 2H 2024.
